Just found a news alert
a company specializing in developing diagnostic blood tests for various autoimmune diseases.
"Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and
management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.
Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008."
Ah, now if they need to conduct clincal trials in the US and need a volunteer proven to have Crohn's disease by several other accepted and proven diagnostic methods. I'M FIRST IN LINE!